Status:
COMPLETED
Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This study is conducted in Europe. The aim of this observational study is to evaluate glycaemic control in subjects with type 2 diabetes using once daily Levemir® as initiation of insulin therapy in H...
Eligibility Criteria
Inclusion
- Patient with type 2 diabetes inadequately controlled by OAD therapy based on the discretion of individual physician
- Patient willing to sign informed consent
- Particular attention should be paid to age limits, indications and contraindications and the drug interactions that are listed within the product labels
Exclusion
- Subjects with diagnosed type 1 diabetes mellitus
- Subjects who are unlikely to comply with observational plan, (e.g., uncooperative attitude, inability to return for further visits)
- Subjects with hypersensitivity to Levemir® or to any of the ingredients
- Women of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant within next 12 months.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
1032 Patients enrolled
Trial Details
Trial ID
NCT00865397
Start Date
February 1 2009
End Date
May 1 2010
Last Update
November 23 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Budapest, Hungary, 1025
2
Novo Nordisk Investigational Site
Budapest, Hungary, H-1025